Search Results for 'dyadic'

DuPont’s $75M acquisition of Dyadic’s industrial biotechnology business closes

DuPont’s $75M acquisition of Dyadic’s industrial biotechnology business closes

January 3, 2016 |

In Florida, Dyadic International announced the closing of the previously announced sale of substantially all of the assets of its Industrial Technology business to DuPont’s Industrial Biosciences business for $75 million in cash.  As previously announced, following the closing, Dyadic intends to focus exclusively on its biopharmaceutical business. In connection with the closing of the […]

Read More

Dyadic reports 21% jump in Q3 product revenue and 69% gross profit gain, in Q3 results

Dyadic reports 21% jump in Q3 product revenue and 69% gross profit gain, in Q3 results

November 15, 2015 |

In Florida, Dyadic reported net Income for Q3 2015 of $1.3 million compared to a net loss of $1.2 million, or ($0.04) per basic and diluted share, for the same period a year ago. At September 30, 2015, cash and cash equivalents were approximately $6.3 million compared to $2.5 million at December 31, 2014. On […]

Read More

DuPont to give Dyadic $75 million Christmas present in thanks for C1 platform

DuPont to give Dyadic $75 million Christmas present in thanks for C1 platform

November 11, 2015 |

In Delaware, DuPont Industrial Biosciences has signed an agreement to purchase enzyme and technology assets from Dyadic International Inc., including Dyadic’s C1 platform, a fungal expression technology for producing enzymes. The transaction will further extend the world-leading biotechnology capabilities of DuPont’s Industrial Biosciences business. Under the terms of the agreement, DuPont will pay $75 million […]

Read More

Consolidation! Dyadic sells industrial technology biz to DuPont for $75M

Consolidation! Dyadic sells industrial technology biz to DuPont for $75M

November 11, 2015 |

As Dyadic cashes out of industrial biotech and retains a C1 license for pharma, DSM and Syngenta also announce a partnership. Companies are girding their loins for the long haul. The Digest takes a look, In Florida, DuPont Industrial Biosciences will acquire substantially all of the enzyme and technology assets Dyadic’s Industrial Technology business for $75 […]

Read More

Dyadic’s C1 beats industry-standard antigen in Sanofi Pasteur trials

Dyadic’s C1 beats industry-standard antigen in Sanofi Pasteur trials

October 11, 2015 |

In Florida, Dyadic received the test results from the mice trials in a research program with Sanofi Pasteur indicating that the C1-produced antigen generated an equal, or better, immune response in mice than the industry standard antigen. At the same time, Dyadic joined the EU-funded Zoonoses Anticipation and Preparedness Initiative, a/k/a/ ZAPI, which aims to develop […]

Read More

Dyadic picks up “low 7-figure” sum in professional liability settlement: much more to come?

Dyadic picks up “low 7-figure” sum in professional liability settlement: much more to come?

August 9, 2015 |

In Florida, Dyadic International has reached a settlement with one of the three remaining defendant law firms in its ongoing professional liability litigation. The Agreement with Defendants Moscowitz & Moscowitz, PA, Norman Moscowitz and Jane Moscowitz was fully executed on July 31, 2015. Payment of the confidential settlement amount to the Company by the Moscowitz […]

Read More

Dyadic announces new EU project to demo ethanol from biomass

Dyadic announces new EU project to demo ethanol from biomass

May 13, 2015 |

In Florida, Dyadic announced details regarding 2G BIOPIC, a new advanced biofuels project funded by the European Commission’s Horizon 2020 program. In the 2G BIOPIC project, Dyadic’s subsidiary Dyadic Netherlands B.V. will work in collaboration with Compagnie Industrielle de Matiere Vegetale (“CIMV”) and five other industry partners to develop, construct and operate a large demonstration-scale facility that […]

Read More

Dyadic’s FY 2014 results show decreased revenues, but tripling of gross profit

Dyadic’s FY 2014 results show decreased revenues, but tripling of gross profit

March 16, 2015 |

In Florida, Dyadic has announced positive financial results for FY 2014, including 12% year-over-year increase in revenue and tripling of gross profit (excluding one-time, upfront license fees). Net product related revenue remained flat at $9.8 million. Sales for the period were driven by growth in the starch and alcohol markets, offset by lower sales to […]

Read More

Dyadic: Biofuels Digest’s 2015 5-Minute Guide

Dyadic: Biofuels Digest’s 2015 5-Minute Guide

March 5, 2015 |

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic’s C1 platform technology enables the development and large scale manufacture of low cost […]

Read More

4 Minutes With…Mark Emalfarb, CEO, Dyadic International

4 Minutes With…Mark Emalfarb, CEO, Dyadic International

September 23, 2014 |

For a guy deep in the gene business, ironic that he started off with jeans. Back in the 70s, Dyadic began as a pioneer and leader in providing ingredients used in the stone-washing of blue jeans. Along the way the company developed its pretty awesome C1 fungal microorganism platform that has been licensed by Codexis and Abengoa amongst […]

Read More